Doctor Julia Schoelermann

35Pharma Inc., Montreal (Canada)

Membership: HFA Member

Contributor content

$HS135, a novel activin and GDF trap, is highly efficacious in preclinical models of pulmonary hypertension and obesity-associated heart failure with preserved ejection fraction$

Presentation

HS135, a novel activin and GDF trap, is highly efficacious in preclinical models of pulmonary hypertension and obesity-associated heart failure with preserved ejection fraction

Explore sponsored resources

Doctor Julia Schoelermann

Contributor content

HS135, a novel activin and GDF trap, is highly efficacious in preclinical models of pulmonary hypertension and obesity-associated heart failure with preserved ejection fraction

ESC 365 is supported by